Lipid composition for encapsulating an active substance, allowing for control of the release rate of said active substance - Patents.com

A lipid composition with beeswax and polyethoxylated fatty acids stabilizes the release profile of active substances against mechanical stress, maintaining consistent release in galenic forms.

JP7577651B2Active Publication Date: 2024-11-05SOC DEXPLOITATION DE PROD POUR LES IND CHEM SEPPIC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2021520588
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-10-19
Filing Date
2019-10-16
Publication Date
2024-11-05
Estimated Expiration
2039-10-16

AI Technical Summary

Technical Problem

Existing encapsulation techniques for active pharmaceutical and nutritional ingredients face challenges in maintaining a controlled release profile when subjected to mechanical stress during the formulation process, leading to altered, accelerated, or delayed release profiles.

Method used

A lipid composition comprising 40% to 99.9% beeswax and up to 10% polyethoxylated fatty acids and lipophilic surfactants, which forms solid particles at ambient temperature, providing protection against mechanical stress and maintaining the release profile.

Benefits of technology

The lipid composition effectively maintains the release profile of active substances under mechanical stress, ensuring consistent and controlled release in final galenic forms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577651000001
    Figure 0007577651000001
  • Figure 0007577651000002
    Figure 0007577651000002
  • Figure 0007577651000003
    Figure 0007577651000003
Patent Text Reader

Abstract

A lipid composition is disclosed, comprising per 100% by weight: - 40 to 99.9% by weight of a complex, which per 100% by weight comprises 90 to 0% by weight of beeswax and up to 10% by weight of at least one other lipid excipient, - 0.1 to 60% by weight of at least one lipophilic surfactant.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a lipid composition, a sustained release composition comprising said lipid composition and allowing to control the release rate of the active substance it comprises, and a method for producing a galenic formulation comprising the sustained release composition. [Background technology]

[0002] Active ingredients developed and used in preparations from the human and veterinary pharmaceutical and food supplement industries are susceptible to environmental factors during the manufacture of the relevant galenical form (in particular the high temperatures used in certain processes, oxidation phenomena, etc.) and / or during the life of said galenical form and / or during consumption within the human or animal body, when said galenical form comes into contact with degradative and / or digestive molecules present in the consumer's body.

[0003] In addition, the molecules constituting all or part of the active principles present in these galenic forms may have organoleptic properties: unpleasant taste, unsuitable odor, etc. which are incompatible with direct consumption.

[0004] Molecules introduced into capsules, hard capsules, tablets or foods to provide a targeted nutritional or therapeutic benefit should not dissolve at the same rate and in the same environment.

[0005] It is for these various reasons in particular that many active molecules are involved in a process called encapsulation. The aim of the encapsulation process is to obtain a composition (C A ) which has the function of protecting at least one active ingredient from undesirable interactions with a particular external environment and transporting said active ingredient to another environment in conditions that allow the release of the active ingredient to achieve its intended therapeutic or nutritional function. This process is a specific example of a process called "direct functionalization" by those skilled in the art.

[0006] The term "direct functionalization" is understood to mean the modification of at least one physicochemical property of an active pharmaceutical ingredient by specific formulation practices and specific processes.

[0007] Among the most well-known encapsulation techniques, mention may be made of those that mainly use hydrophilic compounds, but also those that mainly use hydrophobic compounds, such as the "prilling" technique, also called "spray chilling" or "spray cooling", i.e. a technique that includes an atomization step of a lipid form containing at least one active agent to obtain a solid spherical form, the solidification technique, the hot melt coating technique, the hot melt extrusion technique, the melt granulation technique, the pelletization technique, the spheronization technique, the thermal granulation technique, etc.

[0008] Such "direct functionalization", in particular by encapsulation techniques, can therefore show advantages, for example, in the stabilization of certain compounds that are inherently unstable, such as volatile compounds, preventing oxidation phenomena and overall preserving pharmaceutical or nutritional activity.

[0009] Such steps, especially in the initial "direct functionalization" by encapsulation techniques, can affect the release kinetics of the active agent in the host organism, which is often subsequently desired, especially for taste, odor masking purposes or to obtain a delayed sustained release of the active agent in targeted biological zones within the human or animal body.

[0010] The impact of such a "direct functionalization" step on the release profile of the active agent is considered during the development stage of a therapeutic, prophylactic or nutritional composition.

[0011] However, during the scale-up phase, industrial formulation tools that involve mechanical stress on the galenic form are used, and those skilled in the art recognize that they face repeated challenges of undesirable changes in the sustained release profile compared to formulations initially tested at a scale that does not require the use of such tools.

[0012] As an example, the release profile of an active agent after "direct functionalization" may be significantly altered, accelerated or delayed following use in a process that induces significant mechanical stress, such as a compression process. Thus, the lipid protection induced by the initial "functionalization" may be compromised by weakening of the "protective shell" during compression, thereby inducing an accelerated release profile of the active agent.

[0013] During the downstream steps of galenizing these extended release formulations, it has been observed that the release profile of active agent obtained and carried out after functionalization can be significantly affected and can show significant differences with respect to the release profile of active agent before galenizing.Therefore, the release profile of active agent after functionalization can be significantly changed, accelerated or delayed after carrying out a step related to significant mechanical stress in the process of preparing functionalized active agent, such as, for example, a compression step.More specifically, as an example, the lipid protection induced by initial functionalization can be damaged by the weakening of "protective shell" during compression, which can induce an accelerated and undesirable release profile of active agent. Summary of the Invention [Problem to be solved by the invention]

[0014] To date and as far as the applicant is aware, the skilled artisan does not have a solution that makes it possible to develop and manufacture said formulations prepared by a process comprising at least one step that employs significant mechanical stress, and / or formulations comprising active ingredients released in a delayed or extended manner, the release profile of which is not altered by a preparation process comprising at least one step that exerts significant mechanical stress on the galenic form. [Means for solving the problem]

[0015] The solution of the present invention is a lipid composition, which, per 100% by weight, comprises: - 40% to 99.9% by weight, more particularly 40% to 98% by weight, even more particularly 40% to 95% by weight of a component, which per 100% of its weight comprises 90% to 100% by weight of beeswax and up to 10% by weight of at least one other lipid excipient, - 0.1% to 60% by weight, more particularly 2% to 60% by weight, even more particularly 5% to 60% by weight of at least one lipophilic surfactant chosen from polyethoxylated fatty acids, esters of fatty dibasic acids and polyethylene glycol, esters of polyglycerol and fatty acids, esters of propylene glycol and fatty acids, mixtures of esters of propylene glycol and esters of glycerol, fatty acid diglycerides, sterols and derivatives of sterol, esters of fatty acids and sorbitan, sorbitan, esters of polyethylene glycol and fatty acids, ethers of polyethylene glycol and alkyls, saccharose esters and polyoxyethylene-polyoxypropylene block copolymers; A lipid composition comprising: DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] The composition according to the invention can be in various forms (beads, spheres, scales, flakes, pearls, etc.) that are solid at ambient temperature. It is intended primarily to form active agents in the animal or human pharmaceutical, therapeutic and / or preventive industry sectors, food supplements and / or human and animal food industry.

[0017] For the purposes of the present invention, the term "lipid excipient" is understood to mean an excipient which has a melting point below 120°C, preferably below 100°C, which is solid at ambient temperature (above 15°C and below 30°C) and which is insoluble or sparingly soluble in water.

[0018] The beeswax used in the composition according to the invention is yellow or white in colour, is designated by the E901 number and has a melting point of 60-67°C.

[0019] With respect to lipophilic surfactants, it is expressly stated herein that the terms "lipophilic" and "hydrophilic" are relative terms. An empirical parameter commonly used to characterize the relative lipophilicity and hydrophilicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance (i.e., a value known as "HLB").

[0020] Thus, surfactants with lower HLB values ​​are more lipophilic and have higher solubility in oil, whereas surfactants with higher HLB values ​​are more hydrophilic and have higher solubility in aqueous solutions.

[0021] Using HLB value as an indicator, hydrophilic surfactants are generally considered to be compounds with HLB values ​​of 10 or more, as well as anionic, cationic or zwitterionic compounds for which the HLB scale is generally not applicable. Similarly, lipophilic surfactants are compounds with HLB values ​​of less than about 10. In both cases, the term "about" is included to account for induced variation.

[0022] Optionally, the lipid composition according to the invention may have one or more of the following characteristics: the lipid excipient is selected from animal waxes, vegetable waxes, mineral waxes, synthetic waxes or hydrogenated vegetable oils; the lipophilic surfactants are chosen from esters of fatty acids and sugars; the lipophilic surfactant is a lipophilic surfactant from the family of sorbitan esters, more particularly a member from the group consisting of sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate and sorbitan monooleate, even more particularly sorbitan monopalmitate or sorbitan monostearate, even more particularly sorbitan monostearate; - the composition comprises from 0 to 20% by weight, more particularly from 0% to 10% by weight, of one or more hydrophilic surfactants; - the one or more hydrophilic surfactants are selected from soy lecithin, polyethoxylated sorbitan esters, polyethoxylated alcohols, polyethoxylated acids, polyglycerol esters, glucose ethers and block copolymers of ethylene oxide and propylene oxide; - the lipophilic surfactant is a sorbitan ester and the hydrophilic surfactant is selected from polyethoxylated sorbitan esters; - the composition comprises 80% beeswax, 20% sorbitan stearate; - the composition comprises 94% beeswax, 1% sorbitan stearate and 5% sorbitan oleate polyethoxylated with 20 moles of ethylene oxide (also called polysorbate 80); - the composition comprises 75% beeswax, 20% sorbitan stearate and 5% sorbitan oleate polyethoxylated with 20 moles of ethylene oxide (also called polysorbate 80); - the composition comprises 50% beeswax, 45% sorbitan stearate and 5% sorbitan oleate polyethoxylated with 20 moles of ethylene oxide (also called polysorbate 80); - the composition comprises from 0 to 20% by weight, more particularly from 0 to 10% by weight, of at least one coating adjuvant; the one or more coating aids are selected from diluents, flavourings, appetite stimulants, colouring agents, antioxidants, plasticisers, antifoaming agents and disintegrants;

[0023] Regarding lipid excipients: - animal waxes may include spermaceti, which has a melting point of 52-55°C, lanolin, which has a melting point of 37-44°C, and shellac, which has a melting point of 77-90°C; - vegetable waxes may include carnauba wax with a melting point of 78-88°C, candelilla wax with a melting point of 67-79°C and rice bran wax with a melting point up to 78°C; - mineral waxes may include paraffin having a melting point of 50 to 71 ° C and microcrystalline wax having a melting point of 54 to 102 ° C; - synthetic waxes may include Fischer-Tropsch waxes, polyethylene (or polypropylene) waxes, poly(ethylene oxide) or poly(propylene oxide) waxes, etc.; Hydrogenated vegetable oils may include palm oil, which has a melting point of 58-62°C, and stearin, which has a melting point of 61-65°C.

[0024] Among the lipophilic surfactants, mention may be made of: - esters of fatty acids chosen from stearic acid, palmitic acid, ketostearic acid, arachidic acid and behenic acid with glycerol; - ethers of fatty alcohols, such as the alcohols of stearic, palmitic, ketostearic, arachidic and behenic acid, with sugars, such as reducing sugars, more particularly glucose, xylose, arabinose, mannose or saccharose; divalent salts of fatty acids, such as magnesium, zinc or calcium stearic acid, palmitic acid, ketostearic acid, arachidic acid and behenic acid; - fatty alcohols condensed with propylene oxide and / or butylene oxide; - block copolymers of alkoxides (ethylene, propylene, butylene, etc.) rich in propylene or butylene oxide; - esters of fatty acids chosen from stearic acid, palmitic acid, ketostearic acid, arachidic acid and behenic acid with sugars, for example glucose, sorbitol, mannitose, mannitol, saccharose, mannose, xylitol or xylose; Among the esters of fatty acids and sugars, mention may be made of the esters of fatty acids and sorbitol and of fatty acids and sorbitan.

[0025] Among the sorbitan esters that may be combined with the composition that is the subject of the invention, mention may be made of the following: - sorbitan monolaurate sold by SEPPIC under the trade name Montane™ 20 and by Croda under the trade name Span™ 20, - sorbitan monopalmitate sold by SEPPIC under the trade name Montane™ 40 and by Croda under the trade name Span™ 40; - sorbitan monostearate sold by SEPPIC under the trade name Montane™ 60 and by Croda under the trade name Span™ 60; - sorbitan monooleate sold by SEPPIC under the trade name Montane™ 80 and by Croda under the trade name Span™ 80; - sorbitan trioleate sold by SEPPIC under the trade name Montane® 85 and by Croda under the trade name Span® 85; - sorbitan sesquioleate sold by SEPPIC under the trade name Montane® 83 and by Croda under the trade name Crill® 43, - sorbitan tristearate sold by SEPPIC under the trade name Montane™ 65 and by Croda under the trade name Span™ 65; - Sorbitan monoisostearate sold by SEPPIC under the trade name Montane® 70 and by Croda under the trade name Crill® 6.

[0026] The compositions according to the invention optionally comprise 0-20% of one or more hydrophilic surfactants selected from soy lecithin, ethoxylated sorbitan esters, polyethoxylated alcohols, polyethoxylated acids, polyglycerol esters, glucose ethers and block copolymers of ethylene oxide and propylene oxide.

[0027] Among the ethoxylated sorbitan esters that may be combined with the composition that is the subject of the invention, mention may be made of the following: - sorbitan monolaurate ethoxylated with 20 moles of ethylene oxide, sold by SEPPIC under the trade name Montanox® 20 and by Croda under the trade name Tween® 20; - sorbitan monolaurate ethoxylated with 4 moles of ethylene oxide, sold under the trade name Tween® 21; - sorbitan monolaurate ethoxylated with 6 moles of ethylene oxide, sold by Nikko under the trade name Nikkol® GL-I; - sorbitan monopalmitate ethoxylated with 20 moles of ethylene oxide, sold by SEPPIC under the trade name Montanox® 40 and by Croda under the trade name Tween® 40; - sorbitan monostearate ethoxylated with 20 moles of ethylene oxide, sold by SEPPIC under the trade name Montanox™ 60 and by Croda under the trade name Tween™ 60; - sorbitan tristearate ethoxylated with 20 moles of ethylene oxide, sold by SEPPIC under the trade name Montanox® 65 and by Croda under the trade name Tween® 65; - sorbitan monooleate ethoxylated with 20 moles of ethylene oxide, sold by SEPPIC under the trade name Montanox® 80 and by Croda under the trade name Tween® 80; - sorbitan trioleate ethoxylated with 20 moles of ethylene oxide, sold by SEPPIC under the trade name Montanox® 85 and by Croda under the trade name Tween® 85; - sorbitan monoisostearate ethoxylated with 20 moles of ethylene oxide, sold by SEPPIC under the trade name Montanox® 70 and by Croda under the trade name Tween® 120; - sorbitan monostearate ethoxylated with 4 moles of ethylene oxide, sold by Croda under the trade name Tween® 61; - Sorbitan monooleate ethoxylated with 5 moles of ethylene oxide, sold under the trade name Montanox® 81 by SEPPIC and under the trade name Tween® 81 by Croda.

[0028] Among the ethoxylated fatty alcohols that may be combined as hydrophilic surfactants with the compositions that are the subject of the present invention, there are preferred oleyl alcohol ethoxylated with 2 moles of ethylene oxide, oleyl alcohol ethoxylated with 3 moles of ethylene oxide, oleyl alcohol ethoxylated with 5 moles of ethylene oxide, oleyl alcohol ethoxylated with 10 moles of ethylene oxide, oleyl alcohol ethoxylated with 20 moles of ethylene oxide, lauryl alcohol ethoxylated with 4 moles of ethylene oxide, lauryl alcohol ethoxylated with 7 moles of ethylene oxide, oleyl alcohol ethoxylated with 9 moles of ethylene oxide, Mention may be made of lauryl alcohol ethoxylated with 23 moles of ethylene oxide, cetyl alcohol ethoxylated with 2 moles of ethylene oxide, cetyl alcohol ethoxylated with 10 moles of ethylene oxide, cetyl alcohol ethoxylated with 20 moles of ethylene oxide, stearyl alcohol ethoxylated with 2 moles of ethylene oxide, stearyl alcohol ethoxylated with 10 moles of ethylene oxide, stearyl alcohol ethoxylated with 20 moles of ethylene oxide or stearyl alcohol ethoxylated with 100 moles of ethylene oxide.

[0029] Among the ethoxylated fatty acids which may be combined as hydrophilic surfactants with the compositions which are the subject of the present invention, there are monolauric acids ethoxylated with 4 to 200 moles of ethylene oxide, in particular monolauric acids ethoxylated with 4 moles of ethylene oxide, monolauric acids ethoxylated with 6 moles of ethylene oxide, monolauric acids ethoxylated with 7 moles of ethylene oxide, monolauric acids ethoxylated with 8 moles of ethylene oxide, monolauric acids ethoxylated with 10 moles of ethylene oxide, monolauric acids ethoxylated with 50 moles of ethylene oxide, monolauric acids ethoxylated with 1 ... Monolauric acid ethoxylated with ethylene oxide, monolauric acid ethoxylated with 100 moles of ethylene oxide or monolauric acid ethoxylated with 200 moles of ethylene oxide, monooleic acid ethoxylated with 4 to 200 moles of ethylene oxide, in particular monooleic acid ethoxylated with 1 mole of ethylene oxide, monooleic acid ethoxylated with 2 moles of ethylene oxide, monooleic acid ethoxylated with 4 moles of ethylene oxide, monooleic acid ethoxylated with 5 moles of ethylene oxide, Monooleic acid ethoxylated with 6 moles of ethylene oxide, monooleic acid ethoxylated with 8 moles of ethylene oxide, monooleic acid ethoxylated with 9 moles of ethylene oxide, monooleic acid ethoxylated with 10 moles of ethylene oxide, monooleic acid ethoxylated with 50 moles of ethylene oxide, monooleic acid ethoxylated with 100 moles of ethylene oxide or monooleic acid ethoxylated with 200 moles of ethylene oxide, monooleic acid ethoxylated with 4 to 200 moles of ethylene oxide Monostearic acid ethoxylated with ethylene oxide, in particular monostearic acid ethoxylated with 1 mole of ethylene oxide, monostearic acid ethoxylated with 2 moles of ethylene oxide, monostearic acid ethoxylated with 4 moles of ethylene oxide, monostearic acid ethoxylated with 5 moles of ethylene oxide, monostearic acid ethoxylated with 6 moles of ethylene oxide, monostearic acid ethoxylated with 8 moles of ethylene oxide, monostearic acid ethoxylated with 9 moles of ethylene oxide,Mention may be made of monostearic acid ethoxylated with 10 moles of ethylene oxide, monostearic acid ethoxylated with 50 moles of ethylene oxide, monostearic acid ethoxylated with 100 moles of ethylene oxide, monostearic acid ethoxylated with 200 moles of ethylene oxide, monostearic acid ethoxylated with 300 moles of ethylene oxide or monostearic acid ethoxylated with 1000 moles of ethylene oxide.

[0030] Among the hydrogenated ethoxylated castor oils that may be combined as hydrophilic surfactants with the compositions that are the subject of the present invention, hydrogenated castor oil ethoxylated with 5 moles of ethylene oxide, hydrogenated castor oil ethoxylated with 7 moles of ethylene oxide, hydrogenated castor oil ethoxylated with 10 moles of ethylene oxide, hydrogenated castor oil ethoxylated with 20 moles of ethylene oxide, hydrogenated castor oil ethoxylated with 25 moles of ethylene oxide, hydrogenated castor oil ethoxylated with 30 moles of ethylene oxide, Mention may be made of hydrogenated castor oil ethoxylated with 40 moles of ethylene oxide, hydrogenated castor oil ethoxylated with 45 moles of ethylene oxide, hydrogenated castor oil ethoxylated with 50 moles of ethylene oxide, hydrogenated castor oil ethoxylated with 60 moles of ethylene oxide, hydrogenated castor oil ethoxylated with 80 moles of ethylene oxide or hydrogenated castor oil ethoxylated with 100 moles of ethylene oxide.

[0031] The composition according to the invention optionally comprises 0-20% of at least one coating adjuvant selected from diluents, plasticizers, antifoaming agents and disintegrants.

[0032] Among the diluents that may be combined with the compositions that are the subject of the present invention, mention may be made of lactose, saccharose, mannitol, sorbitol, xylose, xylitol, isomalt, talc, natural starch, silica, silica dioxide and magnesium stearate.

[0033] Among the plasticizers that may be combined with the composition that is the subject of the present invention, mention may be made of glycerol, polypropylene glycol, polyethylene glycol or their derivatives of condensation with fatty acids or fatty alcohols, stearic acid and its derivatives, acetylated monoglycerides, esters of citric acid such as triethyl citrate, acetyltriethyl citrate or acetyltributyl citrate, triacetin, sorbitol or dibutyl seccate.

[0034] Among the antifoaming agents that may be combined with the composition that is the subject of the present invention, mention may be made of silicone derivatives.

[0035] Among the disintegrants that may be combined with the composition that is the subject of the present invention, mention may be made of cellulose derivatives, crospovidone, sodium croscarmellose and sodium starch glycolate.

[0036] It should be noted that other adjuvants such as flavorings, seasonings, appetite stimulants, colorants, pigments and antioxidants may be combined with the compositions that are the subject of the present invention.

[0037] - at least one lipid composition according to the invention, and - at least one active pharmaceutical, prophylactic or dietary substance A sustained release composition (C A ) are also the subject of the present invention.

[0038] This composition according to the present invention (C A ) are preferably intended for oral administration to humans or animals.

[0039] According to another preferred embodiment, the composition according to the invention (C A ) is in the solid state.

[0040] Among the active pharmaceutical ingredients, non-steroidal anti-inflammatory and anti-rheumatic drugs (ketoprofen, ibuprofen, flurbiprofen, indomethacin, phenylbutazone, allopurinol, etc.), analgesics (paracetamol, phenacetin, aspirin, etc.), antitussives (codeine, codetyline, alimemazine, etc.), sterols (hydrocortisone, cortisone, progesterone, testosterone, triamcinolone, dexamethasone, betamethasone, paramethasone, fluocinolone, beclomethasone, etc.), barbiturates (barbital, allobarbital, phenobarbital, pentobarbital, amobarbital, etc.). ), antibiotics (such as pefloxacin, sparfloxacin and derivatives of the quinolone, tetracycline, synergistin, metronidazole class, etc.), drugs intended for the treatment of allergies, bronchial asthma medications, vitamins (vitamin A, vitamin B, vitamin C, vitamin E, vitamins of the D group, vitamin K), antispasmodics and antisecretory agents (omeprazole), cardiovascular agents and cerebrovasodilators (quinacainol, oxprenolol, propanolol, nicergoline, etc.), cerebroprotectants, hepatoprotectants, agents for the treatment of the gastrointestinal tract, vaccines, antihypertensives and cardioprotectants, such as beta-receptor blockers and nitro derivatives.

[0041] Among the nutritional agents, mention may be made of active ingredients usually used in the field of nutrition, such as bioactive lipids, water-soluble or water-dispersible trace element salts, water-soluble or fat-soluble vitamins, prebiotics, probiotics, milk proteins and / or milk protein concentrates, plant or animal enzymes, amino acids, peptides, sugars, seasonings, flavourings, plant ingredients (plant extract of ginger, plant extract of curcumin, plant extract of Hypericum perforatum, plant extract of valerian, blueberry extract, pomegranate extract, Chlorella vulgaris extract, artichoke extract, hibiscus extract).

[0042] Among the physiologically active lipids, mention may be made of phytosterols, such as those extracted from vegetable oils, more particularly extracts of sea buckthorn oil, corn oil or soybean oil; phytosterols isolated from vegetable oils, such as cholestatins consisting of campestrol, stigmasterol and brassicasterol; phytostanols; carotenoids belonging to the family of terpenoids, extracted from algae, green plants, fungi or bacteria; highly unsaturated fatty acids of the omega-3 group, such as α-linolenic acid, eicosapentaenoic acid or docosahexanoic acid; highly unsaturated fatty acids of the omega-6 group, such as linoleic acid, γ-linolenic acid, acid.

[0043] Among the water-soluble or water-dispersible trace element salts used in ingestible solid forms coated with the coating composition that is the subject of the present invention, there may be mentioned ferrous carbide, ferrous chloride tetrahydrate, ferric chloride hexahydrate, ferrous citrate hexahydrate, ferrous fumarate, ferrous lactate tetrahydrate, ferrous sulfate monohydrate, ferrous sulfate heptahydrate, ferrous chelate of amino acids hydrate, ferrous glycine chelate; calcium iodate hexahydrate, calcium iodate anhydrous; sodium iodide, potassium iodide; cobalt acetate tetrahydrate, basic cobalt carbonate monohydrate, cobalt carbonate hexahydrate, cobalt sulfate heptahydrate, cobalt sulfate monohydrate, cobalt nitrate hexahydrate; cupric acetate monohydrate. , basic copper carbonate monohydrate, copper(II) chloride dihydrate, copper methionate, copper(II) sulfate pentahydrate, copper(I) chelate of amino acids hydrate, copper(I) chelate of glycine hydrate, copper chelate of hydroxy analogue of methionine; manganous carbonate, manganous chloride tetrahydrate, manganous hydrogen phosphate trihydrate, manganous sulfate tetrahydrate, manganous sulfate monohydrate, manganous chelate of amino acids hydrate, manganous chelate of glycine hydrate, manganous chelate of hydroxy analogue of methionine; ammonium molybdate, sodium molybdate, sodium selenite, sodium selenate; Saccharomyces cerevisiae (Saccharomyces cerevisiae), selenomethionine (inactive selenium yeast) and organic forms of selenium produced by Saccharomyces cerevisiae (inactive selenium yeast).

[0044] Among the inorganic salts, mention may be made of the salts of metal cations, such as the sodium, potassium, calcium, magnesium, zinc, manganese, iron, copper, cobalt, silver, barium, zirconium and strontium cations, and of organic anions, such as the salts of edible organic anions having at least one carboxylic acid function of the carboxylate type selected from the members of the group consisting of anions derived from glycolic acid, citric acid, tartaric acid, salicylic acid, lactic acid, mandelic acid, ascorbic acid, pyruvic acid, fumaric acid, glycerophosphoric acid, retinoic acid, benzoic acid, kojic acid, malic acid, gluconic acid, galacturonic acid, propionic acid, heptanoic acid, 4-aminobenzoic acid, cinnamic acid, benzalmalonic acid, aspartic acid and glutamic acid.

[0045] Among the inorganic salts, mention may be made in particular of zinc gluconate, calcium gluconate, manganese gluconate, copper gluconate, magnesium aspartate, calcium aspartate, calcium glycerophosphate, calcium glycerophosphate, magnesium glycerophosphate.

[0046] Among the water-soluble or fat-soluble vitamins, there are preferred vitamin A, more particularly in the form of retinol, retinyl acetate, retinyl palmitate or β-carotene, vitamin D2, more particularly in the form of ergocalciferol or -hydroxycalciferol, vitamin D3, more particularly in the form of cholecalciferol, vitamin K, more particularly in the form of phylloquinone (phytomenadione) or menaquinone, vitamin B1, more particularly thiamine hydrochloride, thiamine mononitrate, thiamine phosphate chloride or vitamin B1 in the form of thiamine pyrophosphate chloride, vitamin B2, more particularly in the form of riboflavin or riboflavin 5'-phosphate sodium, vitamin B6, more particularly in the form of pyridoxine hydrochloride, pyridoxine 5'-phosphate or pyridoxal 5'-phosphate, vitamin B12, more particularly in the form of cyanocobalamin, hydroxocobalamin, 5'-deoxyadenosylcobalamin or methylcobalamin, vitamin C, more particularly L-ascorbic acid, L-ascorbic acid Vitamin C in the form of sodium, calcium L-ascorbate, potassium L-ascorbate, the calcium salt of 6-palmitoyl-L-ascorbic acid or sodium ascorbyl monophosphate; pantothenic acid, more particularly in the form of calcium D-pantothenate, sodium D-pantothenate, dexpanthenol or pantethine; vitamin PP, more particularly in the form of nicotinic acid, niacin, nicotinamide or inositol hexanicotinate (inositol hexanicotinate ester). Mention may be made of PP, vitamin B9, more particularly in the form of folic acid or a folate, more particularly in the form of pteroylmonoglutamic acid, calcium L-methylfolate or (6S)-5-methyltetrahydrofolic acid in the form of a glucosamine salt, vitamin H2, B7 or BW, more particularly in the form of biotin, choline, more particularly choline chloride, choline dihydrogen citrate or choline bitartrate, inositol, carnitine, more particularly L-carnitine or L-carnitine L-tartrate or taurine.

[0047] Among the prebiotics, mention may be made of inulin, transgalactooligosaccharides, fructans and mannooligosaccharides.

[0048] Among the probiotics, mention may be made of Saccharomyces cerevisiae, Bacillus cereus var. toyoi, various strains of Bacillus subtilis alone or in combination with Bacillus licheniformis, or Enteroccocus faecium, strains of lactic acid bacteria, more particularly lactobacilli, bifidobacteria and streptococci. These strains of microorganisms are generally combined with a solid carrier, such as calcium carbonate, dextrose or sorbitol.

[0049] Among the proteins and / or protein concentrates, mention may be made of milk proteins obtained from milk digestion, such as colostrum in powder form, lyophilized or atomized, whey in powder form, purified or enriched fractions for IgG, lactoferrin or lactoperoxidase. Among the plant or animal enzymes, mention may be made of promutase, superoxide dismutase (SOD), 3-phytase, 6-phytase, endo-1,4-β-glucanase, endo-1,4-β-xylanase or other enzymes that improve or promote digestion.

[0050] Among the peptides, mention may be made of avocado peptides, lupin peptides, quinoa peptides, maca peptides, fermented or unfermented soybean peptides, rice peptides, peptides present in Acacia macrostachia seed extracts or peptides present in Passiflora seed extracts.

[0051] Among the amino acids, mention may be made of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, hydroxyproline, pyrrolysine, selenocysteine, serine, threonine, tryptophan, tyrosine, valine, sarcosine or ornithine.

[0052] Among the sugars, mention may be made of water-soluble polysaccharides or low molecular weight sugars, such as oligosaccharides or mono- or disaccharides, such as glucose, lactose or dextrose.

[0053] Among the chemical flavour enhancers, mention may be made of glutamates, such as glutamic acid, monosodium glutamate, monopotassium glutamate, calcium diglutamate, ammonium glutamate or magnesium diglutamate; guanylates, such as guanylic acid (guanosine monophosphate), disodium guanylate, dipotassium guanylate or calcium guanylate, inosinates, such as inosinic acid, disodium inosinate, dipotassium inosinate or calcium inosinate or intense sweeteners, such as stevia extract or rebaudioside.

[0054] The use of the lipid composition according to the invention for the inclusion of active pharmaceutical, therapeutic, prophylactic or dietary substances for humans or animals in galenic preparations is also a subject of the present invention.

[0055] For the purposes of the present invention, the term "encapsulation" is understood to mean an operation that makes it possible to bring together a lipid composition and one or more active ingredients. The active agents may be located in a shell formed by this "cooled" lipid composition or may be dispersed in the lipid composition.

[0056] Finally, a final subject of the invention is a method for producing a galenical preparation containing a composition (CA) according to the invention, comprising at least a) preparing a lipid composition according to the present invention, b) mixing and encapsulating an active pharmaceutical, prophylactic or dietary substance with the lipid composition prepared in step a) to obtain a composition according to the invention (C A ), and c) subjecting the composition (C) prepared in step b) to mechanical stress. A Steps to form Galen The method includes:

[0057] The term "mechanical stress" is understood to mean a tension or pressure acting on a material and capable of modifying the shape or properties of said material. In the context of the present invention, this is the stress applied to the composition CA during its use (step c) for the preparation of the final galenic form.

[0058] Furthermore, it should be noted that in the context of the present invention, the release profile of the active substance in the final galenic form is similar or not significantly different from the release profile of the active substance in composition CA. In particular, it is for the lipid composition according to the invention that little or no change in resistance to mechanical stress and therefore in the release profile is observed.

[0059] Among the encapsulation processes used in step b), mention may be made of prilling, spray chilling or spray cooling, spray congealing, hot melt coating, hot melt extrusion, melt granulation, pelletizing, spheronization or thermal granulation techniques, etc. (insert French translation where possible).

[0060] The term "prilling" refers to the process of coating by dissolving or dispersing the active ingredient in a molten lipid composition which is then sprayed into ambient or chilled air or liquid.

[0061] The "spray chilling", "spray cooling" and "spray congealing" processes are specific processes of the prilling process.

[0062] The term "hot melt coating" refers to a coating process by spraying a molten lipid composition onto solid particles of an active agent or a mixture of active agents.

[0063] Optionally, the manufacturing process according to the invention may have one or more of the following characteristics: - the mixing and encapsulation step b) comprises a first sub-step of heating the lipid composition prepared in step a) to a temperature of 10-15°C above the highest melting point of the various components of said lipid composition, in order to melt said lipid composition, a second sub-step of mixing the melted lipid composition with the active substance in dispersed or melted form, and spraying the composition obtained in the second sub-step into ambient or cooled air or a cooled liquid, in order to obtain a composition (C A The term "ambient air" is understood to mean air at ambient temperature, generally around 25° C.; the term "cooled air" or "cooled liquid" is understood to mean air or liquid at a temperature below ambient temperature, in other words below 25° C. - The galenic forming step involving mechanical stress is selected from processes giving solid oral dosage forms, such as compression, forming into hard capsules (capsule filling / molding), compacting (consolidation, roller compaction), packaging, placing into sachets, forming into sticks (stick and sachet filling), extrusion, granulation and pelletizing. These techniques can result in the production of the following forms (non-exhaustive): oral powders, beads, hard capsules (capsules), granules, sugar-coated granules, pearls, pellets, spheres (spherules), tablets, sachets, sticks, chews, gums, chewable tablets, chewing gums.

[0064] The lipid composition according to the invention makes it possible to form active substances by various coating techniques and unexpectedly induces a stability of the release profile of the active substances so coated, compared to the release profiles of active substances whose galenic forms have not previously been obtained by processes involving a step of mechanical stress.

[0065] In other words, the subject matter of the present invention makes it possible to maintain the initially desired release profile of the active substance, regardless of whether a downstream galenic formulation process is carried out and regardless of the mechanical stresses applied to bring the active agent into the final product form (mixing, compaction, formulation into hard capsules, formulation into sticks, tableting, etc.).

[0066] For the purposes of the present invention, the term "forming by a technique for coating an active agent" is understood to mean any primary technique or any process making it possible to give to the composition comprising said active agent a physical form, preferably a form that is solid at ambient temperature.

[0067] The examples which follow illustrate the invention without, however, limiting it. EXAMPLES

[0068] The limits of the encapsulation composition detailed above, which induce resistance properties against mechanical stresses of the downstream galenic steps, are established by setting up an analysis as follows.

[0069] The active agent is selected as the main model active agent. It should be noted that the term "active agent" is understood to mean an active substance. This active substance is caffeine, which has an average solubility of 20-25 g / l in water at ambient temperature (25°C). Molecular formula: C8H10N4O2; Molecular weight: 194.194 g / mol.

[0070] This active agent is incorporated into the composition that is the subject of the present invention by rotary disc prilling technology, at a rate of 20% to 30%.

[0071] Rotating disc prilling technique: process for preparing composition M1 For each test, a waxy liquid dispersion is prepared that contains the following: the composition which is the subject of the invention in molten form; Model surfactants in dispersed solid form It should be noted that in general, the active agent can be present in dispersed or liquid form depending on its melting point value.

[0072] In this regard, the "pre-dispersion" which is the result of mixing in the melted and / or liquid state of the various elements of the composition that is the subject of the present invention is carried out beforehand: mixture preparation M0.

[0073] The temperature at which this pre-dispersion and then the reconstituted dispersion is held must be adjusted to be 10-15°C above the highest melting point of the various components of the composition. Before starting the manufacturing process, the active agent is added, in this case dispersed, by mechanical stirring while maintaining the previously established temperature.

[0074] Then, a rotating disk prilling process is carried out. A thermally insulated pipe delivers the dispersion to the spray nozzles located in the space / tower, where after atomization, fine droplets are created. These fine droplets are then solidified in a flow of cooled ambient air, leading to the formation of small spherical beads, characterized in that 50% by volume of these beads have a diameter of 300-500 μm. It is noted that the particle size profile of the beads is measured by a Mastersizer 3000 laser particle sizer from Malvern, used in the drying route at a pressure of 1 bar.

[0075] Silicon dioxide or another flow / anti-sticking agent can optionally be added beforehand to the microbeads so produced to facilitate subsequent handling.

[0076] Similarly, sieving over a 500 μm sieve may be performed to remove undesirable aggregates / residues having particle diameters of 500 μm or greater.

[0077] The microbeads thus obtained are then incorporated into a mixture of excipients of a grade compatible with the tablet-type galenization process. The tablet form is chosen as a model final galenization process since it represents one of the most extreme cases in terms of induced mechanical stresses.

[0078] Tableting is carried out on a fitted Dott Bonapace reciprocating single-punch press or on a fitted Riva Piccola rotary 8-punch press with application of a compression force that can be varied from 5 to 20 kN, thus producing 500 mg tablets with a breaking strength of 80 to 120 N.

[0079] Demonstration of technical impact: The release profile of the active agent coated with the composition that is the subject of the present invention and then incorporated into a tablet format is established by means of an Erweka dissolution tester, according to the recommendations of the European Pharmacopoeia, edition 7.3, paragraph 2.9.3.

[0080] The dissolution medium of choice is a phosphate buffer solution at pH 7.2 maintained at a temperature of 37° C. Samples are taken periodically for up to 6 hours. The samples are then analyzed by reverse phase HPLC analysis with UV detection to determine the amount of active agent present in each sample and thus establish the dissolution profile of the sample being evaluated.

[0081] Dissolution profiles in comparison from composition to composition or before / after application of mechanical stress are compared to determine the presence or absence of differences in the two profiles relative to each other or one profile relative to a control profile.

[0082] As such, the two profiles are deemed to be similar or not significantly different, and therefore the composition is deemed to provide improved resistance to mechanical stress if:

[0083] Time to time difference, the calculation of which is as follows: abs[%release(Txi)tab-%release(Txi)μ beads]≦y% During the ceremony, % Release(Txi)tab = % of active agent released at sampling point Txi when the formulation was subjected to the tabletting process. % Release (Txi) μbeads = % of active agent released at sampling point Txi when the formulation is not subjected to mechanical stress. Also, the value y is 30+ / -2% or less for dissolution times up to 2 hours and 20+ / -2% or less for the remaining evaluation times.

[0084] Profiles can be considered similar if there is a difference of 15% or less throughout the dissolution test.

[0085] The percentage of change between the values ​​before and after the application of mechanical stress is less than 30% from a dissolution time of 3 hours. The calculation is as follows:

number

[0086] Example 1 In this example, the lipid composition contains the same beeswax as component A, the same amount of polysorbate 80 and the same proportions of different lipophilic surfactants as component B. The composition of the lipid compositions prepared is reported in Table 1 below. These lipid compositions are used for coating by the prilling process detailed above, with caffeine as active ingredient. The purpose of this example is to show the effectiveness of the combination of beeswax and a specific lipophilic surfactant for coating by the prilling process of the active agent caffeine, by observing the maintenance or non-maintenance of the release profile over time, as the case may be, as they are not considered as suitable specific combinations of beeswax and lipophilic surfactants before undergoing the compression step.

[0087] [Table 1]

[0088] The active agent is dispersed at 20% in the composition. The prilling process is carried out.

[0089] Microbeads with a median diameter of 350-400 μm are obtained.

[0090] These microbeads are stable for a minimum of 28 months at ambient temperature protected from light.

[0091] The dissolution profile of the microbeads is studied after the manufacturing process or after a minimum shelf life of 28 months. Various sampling times are performed and a comparison of the profiles is made at the 120 minute time point.

[0092] Table 2 below shows the percentage values ​​of caffeine released at the 120 minute sampling point.

[0093] [Table 2]

[0094] Table 3 below shows the time vs. time difference at the 120 minute sampling point. * Indicates the value of.

[0095] [Table 3]

[0096] ( * ): The specific definition of time vs. time difference should be noted herein when comparing the release profile at TO and the release profile after the stabilization period. Therefore, the time vs. time difference is redefined herein as obtained from the following calculation: abs[%release(120x'i)μbeads-%release(120xi)μbeads]y% During the ceremony, % Release(120x'i)μbeads = % of active agent released at the 120 minute sampling point when the formulation is stored at ambient temperature for a defined period of time. % Release(120xi)μbeads=% of active agent released at the 120 minute sampling point when the formulation is not stored, i.e., the value at TO from the preparation of the microbeads.

[0097] Two profiles are judged to be comparable if the time-over-time difference in the y values ​​is 20+ / -2% or less at the sampling points considered.

[0098] Profiles can be deemed similar if the time-to-time difference is 15% or less.

[0099] With regard to this example, it can be observed that compositions CL1' and CL2' make it possible to maintain over time the release profile of the active agent caffeine contained in the microbeads obtained from the prilling process. Composition CL3' containing glycerol monostearate as component B can already be neglected.

[0100] Example 2 In this example, the lipid composition contains waxes and oils from different sources as component A, which are used for coating by the prilling process of the active agent caffeine as detailed above. The purpose of this example is to demonstrate the specificity of beeswax in combination with other ingredients in terms of making it possible to maintain a similar / or not significantly different release profile of the coated active agent after the galenic process / subsequent mechanical stress.

[0101] Therefore, the following compositions are used in parallel (Table 4):

[0102] [Table 4]

[0103] The active agent is dispersed at 20% in the composition. The prilling process is carried out.

[0104] Microbeads with a median diameter of 350-400 μm are obtained.

[0105] These microbeads are then introduced into the mixture for the tablets. 500 mg tablets with a diameter of 11 mm are produced according to the following composition: for 40% by weight of microbeads, 27% by weight of microcrystalline cellulose, 29% by weight of calcium hydrogen phosphate dihydrate, 3% by weight of crospovidone and 1% by weight of magnesium stearate are added.

[0106] The dissolution profile of the microbeads before and after the compression process is investigated. The sampling times are as follows: 60, 120, 180, 240, 300 and 360 min.

[0107] Table 5 below shows the percentage values ​​of caffeine released as a function of time.

[0108] [Table 5]

[0109] Table 6 below shows the time vs. time difference values ​​and percentage changes from 180 minutes onwards.

[0110] [Table 6]

[0111] With regard to this example, it can be seen that only composition CL1 allows for an improved resistance to mechanical stress, which is exemplified herein by the tablet galenic formation process.

[0112] Example 3 In this example, the lipid composition contains as component A the ratio of beeswax and candelilla wax used for coating the active agent caffeine by the prilling process. The purpose of this example is to demonstrate the possibility of mixing beeswax with other lipid compounds up to certain ratios, combined with other ingredients, while making it possible to maintain a similar / or not significantly different release profile of the coated active agent after the galenic process / subsequent mechanical stress.

[0113] Thus, the following compositions are used in parallel:

[0114] [Table 7]

[0115] The active agent is dispersed at 20% in the composition. The prilling process is carried out.

[0116] Microbeads with a median diameter of 350-400 μm are obtained.

[0117] These microbeads are then introduced into the mixture for tablets prepared according to the procedure described in Example 2. 500 mg tablets with a diameter of 11 mm are thus produced.

[0118] The dissolution profile of the microbeads before and after the compression process is investigated. The sampling times are as follows: 60, 120, 180, 240, 300 and 360 min.

[0119] The table below shows the percentage values ​​of caffeine released as a function of time.

[0120] [Table 8]

[0121] The table below shows the time vs. time difference values ​​and percentage changes from 180 minutes onwards.

[0122] [Table 9]

[0123] In this example, it can be seen that compositions CL1 and CL5 allow an improvement in the resistance to mechanical stress with a profile similar to that of composition CL1 and not significantly different from that of composition CL5.

[0124] Example 4 In this example, it is a lipid composition having component A (beeswax) and component B (hydrophilic surfactant of sorbitan ester type) used for the coating by the prilling process of the active agent caffeine.

[0125] The purpose of this example is to demonstrate the feasibility of mixing components A and B in specific ratios with respect to maintaining a similar and / or not significantly different release profile of the coated active agent after the galenic formation process / subsequent mechanical stress.

[0126] Thus, the following compositions are used in parallel:

[0127] [Table 10]

[0128] The active agent is dispersed at 20% in the composition. The prilling process is carried out.

[0129] Microbeads with a median diameter of 350-400 μm are obtained.

[0130] These microbeads are then introduced into the mixture for tablets prepared according to the procedure described in Example 2. 500 mg tablets with a diameter of 11 mm are thus produced.

[0131] The dissolution profile of the microbeads before and after the compression process is investigated. The sampling times are as follows: 30, 60, 120, 180, 240, 300 and 360 minutes.

[0132] Table 11 below shows the percentage values ​​of caffeine released as a function of time.

[0133] [Table 11]

[0134] The table below shows the time vs. time difference values ​​and percentage changes from 180 minutes onwards.

[0135] [Table 12]

[0136] With regard to this example, it can be seen that compositions CL8 and CL9 allow an improvement in the resistance to mechanical stress. It is observed that with composition CL7, a minimum amount of component B is required.

Claims

1. A lipid composition for use in a galenic formulation formed with mechanical stress selected from compression, compaction, extrusion and pelleting, comprising, per 100% by weight: - from 40% to 99.9% by weight of a component comprising, per 100% of its weight, from 90% to 100% by weight of beeswax and up to 10% by weight of at least one other lipid excipient; - 0.1% to 60% by weight of at least one lipophilic surfactant chosen from sorbitan esters chosen from sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate and sorbitan monooleate, and glycerol distearate; A lipid composition comprising:

2. 2. The lipid composition according to claim 1, characterized in that the lipid excipient is selected from animal waxes, vegetable waxes, mineral waxes, synthetic waxes or hydrogenated vegetable oils.

3. 3. The lipid composition according to claim 1 or 2, characterized in that the lipophilic surfactant is selected from the sorbitan esters.

4. 4. The lipid composition according to claim 1 or 3, characterized in that the lipophilic surfactant is a lipophilic surfactant from sorbitan monostearate.

5. A lipid composition according to any one of claims 1 to 4, characterized in that it contains from 0 to 20% of one or more hydrophilic surfactants.

6. 6. The lipid composition according to claim 5, characterized in that the one or more hydrophilic surfactants are selected from soy lecithin, ethoxylated sorbitan esters, polyethoxylated alcohols, polyethoxylated acids, polyglycerol esters, glucose ethers and block copolymers of ethylene oxide and propylene oxide.

7. 6. The lipid composition according to claim 5, characterized in that the lipophilic surfactant is a sorbitan ester and the hydrophilic surfactant is selected from polyethoxylated sorbitan esters.

8. - 75% beeswax, 20% sorbitan monostearate, and 5% sorbitan oleate polyethoxylated with 20 moles of ethylene oxide (or polysorbate 80) The lipid composition according to claim 7, characterized in that it comprises:

9. - 50% beeswax, 45% sorbitan monostearate, and 5% sorbitan oleate polyethoxylated with 20 moles of ethylene oxide (or polysorbate 80) The lipid composition according to claim 7, characterized in that it comprises:

10. A lipid composition according to any one of claims 1 to 7, characterized in that it comprises from 0 to 20% of at least one coating adjuvant.

11. The lipid composition according to claim 10, characterized in that the one or more coating adjuvants are selected from diluents, flavorings, appetite stimulants, colorants, antioxidants, plasticizers, antifoaming agents and disintegrants.

12. - at least one lipid composition according to any one of claims 1 to 11, and - at least one active pharmaceutical, prophylactic or dietary substance A sustained release composition (C A ) comprising at least a) preparing a lipid composition according to any one of claims 1 to 11, b) mixing and encapsulating an active pharmaceutical, prophylactic or dietary substance with the lipid composition prepared in step a) to obtain said composition (C A ), and c) subjecting the composition (C) prepared in step b) to mechanical stress. A ) Galenic formation step Including, The method, wherein said galenizing step involving mechanical stress is selected from compression, compacting, extrusion and pelletizing.

13. The mixing and encapsulation step b) comprises: a first substep of heating the lipid composition prepared in step a) to a temperature 10-15° C. above the highest melting point of the various components of said lipid composition in order to melt said lipid composition, - a second substep of mixing said melted lipid composition with said active substance in dispersed or melted form, and - spraying the composition obtained in the second sub-step into the surroundings or into cooled air or a cooled liquid to obtain a composition (C A A third substep of obtaining solidified particles of The method of claim 12, comprising:

Citation Information

Patent Citations

  • Bleomycin solid preparation

    JP1979110318A

  • Oil and fat composition containing dipeptide sweetening agent

    JP1982099170A

  • Dental floss provided with chemotherapeutic medicine

    JP1995136192A

  • Pharmaceutical microspheres of valproic acid for oral administration

    JP2000504038A

  • Sustained release composition for macromolecular proteins

    WO1991005548A1